CureVac NV (CVAC) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1245009,
    "name": "CureVac NV",
    "stock_name": "CureVac NV",
    "full_name": "CureVac NV",
    "name_url": "stocks-analysis/curevac-nv",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "5.12",
    "chg": 0.01,
    "chgp": "0.2%",
    "dir": 1,
    "prev_price": "5.11",
    "mcapval": "1,204.67",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "NL0015436031",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.18 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/curevac-nv-1245009-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "CureVac NV Faces Valuation Shift Amid Declining Financial Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/curevac-nv-stock-downgraded-to-sell-amid-significant-financial-declines-3731765",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CureVacNV_mojoScore_3731765.png",
        "date": "2025-11-26 15:53:20",
        "description": "CureVac NV, a small-cap biotechnology firm, has undergone a recent evaluation adjustment reflecting changes in its valuation metrics. While the company demonstrates strong efficiency in generating profits, it faces challenges with declining net sales and profitability, highlighting the complexities of its financial situation."
      },
      {
        "title": "Is CureVac NV overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-curevac-nv-overvalued-or-undervalued-3651113",
        "imagepath": "",
        "date": "2025-10-28 11:13:17",
        "description": "As of 24 October 2025, the valuation grade for CureVac NV has moved from attractive to very attractive, indicating a strong improvement in its perceived value. The company is currently considered undervalued, supported by a P/E ratio of 5, an EV to EBITDA of 1.90, and a PEG ratio of 0.03, which suggests significant growth potential relative to its price. \n\nIn comparison to its peers, CureVac NV's P/E ratio is notably lower than PTC Therapeutics, Inc. at 5.85 and Harmony Biosciences Holdings, Inc. at 11.40, reinforcing its undervaluation. Additionally, while CureVac has experienced a year-to-date return of 57.18%, significantly outperforming the S&P 500's return of 15.47%, its long-term performance over the past five years shows a decline of 89.29%, highlighting volatility. Overall, these metrics suggest that CureVac NV is positioned as an attractive investment opportunity within the pharmaceuticals and biot..."
      },
      {
        "title": "Is CureVac NV overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-curevac-nv-overvalued-or-undervalued-3647618",
        "imagepath": "",
        "date": "2025-10-27 11:13:22",
        "description": "As of 24 October 2025, the valuation grade for CureVac NV has moved from attractive to very attractive, indicating a strong improvement in its perceived value. The company appears to be undervalued with a P/E ratio of 5, significantly lower than its peer PTC Therapeutics, Inc., which has a P/E of 5.85, and Harmony Biosciences Holdings, Inc. at 11.40. Additionally, CureVac's EV to EBITDA ratio of 1.90 and a PEG ratio of 0.03 further support this undervaluation narrative, suggesting that the stock is priced favorably compared to its growth potential.\n\nIn terms of recent performance, CureVac NV has demonstrated a remarkable year-to-date return of 57.18%, vastly outperforming the S&P 500's return of 15.47% over the same period. However, it has faced challenges over the longer term, with a three-year return of -27.96% compared to the S&P 500's 78.85%. Overall, the combination of low valuation ratios and strong r..."
      },
      {
        "title": "Is CureVac NV overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-curevac-nv-overvalued-or-undervalued-3646157",
        "imagepath": "",
        "date": "2025-10-26 11:09:56",
        "description": "As of 24 October 2025, the valuation grade for CureVac NV has moved from attractive to very attractive. The company appears to be undervalued, supported by a P/E ratio of 5, an EV to EBITDA ratio of 1.90, and an impressive PEG ratio of 0.03. In comparison with peers, PTC Therapeutics, Inc. has a P/E of 5.85 and an EV to EBITDA of 3.17, while Harmony Biosciences Holdings, Inc. shows a P/E of 11.40 and an EV to EBITDA of 6.94, indicating that CureVac NV is trading at a significant discount relative to its industry peers.\n\nCureVac NV has delivered a year-to-date return of 57.18%, significantly outperforming the S&P 500's return of 15.47%, which reinforces the notion that the stock is undervalued given its strong performance metrics and favorable valuation ratios...."
      },
      {
        "title": "Is CureVac NV technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-curevac-nv-technically-bullish-or-bearish-3548972",
        "imagepath": "",
        "date": "2025-09-20 20:29:39",
        "description": "As of 18 August 2025, the technical trend for CureVac NV has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The Bollinger Bands are bullish on the weekly and mildly bullish on the monthly, supporting a positive outlook. Daily moving averages are mildly bullish, suggesting some short-term strength. However, the KST is mildly bearish on the weekly and bullish on the monthly, adding to the mixed sentiment. \n\nCureVac has shown strong performance year-to-date with a return of 56.89%, significantly outperforming the S&P 500's 12.22%. Over the past year, it also outperformed the benchmark with a return of 62.61% compared to the S&P 500's 17.14%. However, longer-term returns over 3, 5, and 10 years are notably negative compared to the S&P 500. Overall, the current stance is mildly bullish, driven by the mixed indicators ..."
      },
      {
        "title": "Is CureVac NV overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-curevac-nv-overvalued-or-undervalued-3544538",
        "imagepath": "",
        "date": "2025-09-20 18:48:53",
        "description": "As of 12 September 2025, the valuation grade for CureVac NV has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company appears undervalued, supported by a P/E ratio of 5, an EV to EBITDA of 1.90, and a PEG ratio of 0.03, all of which are considerably lower than industry norms. In comparison, PTC Therapeutics, Inc. has a P/E of 5.85 and an EV to EBITDA of 3.17, while Harmony Biosciences Holdings, Inc. shows a P/E of 11.40, highlighting CureVac's relative valuation advantage.\n\nDespite recent underperformance over shorter time frames, with a 1-week return of -0.74% compared to the S&P 500's 1.05%, CureVac has outperformed the index year-to-date with a return of 56.89% versus 12.22% for the S&P 500. This suggests that while the stock may be experiencing volatility, its long-term potential remains strong, reinforcing the view that it is currently underv..."
      },
      {
        "title": "CureVac NV Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/curevac-nvs-valuation-grade-upgraded-from-attractive-to-very-attractive-amid-strong-performance-3522704",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/CureVacNV_valuationdot_3522704.png",
        "date": "2025-09-16 18:03:30",
        "description": "CureVac NV, a small-cap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation metrics. With a P/E ratio of 5 and strong returns on capital and equity, the company demonstrates operational efficiency and profitability, positioning itself competitively against peers in the industry."
      }
    ],
    "total": 11,
    "sid": "1245009",
    "stock_news_url": "https://www.marketsmojo.com/news/curevac-nv-1245009"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

CureVac NV Faces Valuation Shift Amid Declining Financial Performance Indicators

2025-11-26 15:53:20

CureVac NV, a small-cap biotechnology firm, has undergone a recent evaluation adjustment reflecting changes in its valuation metrics. While the company demonstrates strong efficiency in generating profits, it faces challenges with declining net sales and profitability, highlighting the complexities of its financial situation.

Is CureVac NV overvalued or undervalued?

2025-10-28 11:13:17

As of 24 October 2025, the valuation grade for CureVac NV has moved from attractive to very attractive, indicating a strong improvement in its perceived value. The company is currently considered undervalued, supported by a P/E ratio of 5, an EV to EBITDA of 1.90, and a PEG ratio of 0.03, which suggests significant growth potential relative to its price. In comparison to its peers, CureVac NV's P/E ratio is notably lower than PTC Therapeutics, Inc. at 5.85 and Harmony Biosciences Holdings, Inc. at 11.40, reinforcing its undervaluation. Additionally, while CureVac has experienced a year-to-date return of 57.18%, significantly outperforming the S&P 500's return of 15.47%, its long-term performance over the past five years shows a decline of 89.29%, highlighting volatility. Overall, these metrics suggest that CureVac NV is positioned as an attractive investment opportunity within the pharmaceuticals and biot...

Is CureVac NV overvalued or undervalued?

2025-10-27 11:13:22

As of 24 October 2025, the valuation grade for CureVac NV has moved from attractive to very attractive, indicating a strong improvement in its perceived value. The company appears to be undervalued with a P/E ratio of 5, significantly lower than its peer PTC Therapeutics, Inc., which has a P/E of 5.85, and Harmony Biosciences Holdings, Inc. at 11.40. Additionally, CureVac's EV to EBITDA ratio of 1.90 and a PEG ratio of 0.03 further support this undervaluation narrative, suggesting that the stock is priced favorably compared to its growth potential. In terms of recent performance, CureVac NV has demonstrated a remarkable year-to-date return of 57.18%, vastly outperforming the S&P 500's return of 15.47% over the same period. However, it has faced challenges over the longer term, with a three-year return of -27.96% compared to the S&P 500's 78.85%. Overall, the combination of low valuation ratios and strong r...

Is CureVac NV overvalued or undervalued?

2025-10-26 11:09:56

As of 24 October 2025, the valuation grade for CureVac NV has moved from attractive to very attractive. The company appears to be undervalued, supported by a P/E ratio of 5, an EV to EBITDA ratio of 1.90, and an impressive PEG ratio of 0.03. In comparison with peers, PTC Therapeutics, Inc. has a P/E of 5.85 and an EV to EBITDA of 3.17, while Harmony Biosciences Holdings, Inc. shows a P/E of 11.40 and an EV to EBITDA of 6.94, indicating that CureVac NV is trading at a significant discount relative to its industry peers. CureVac NV has delivered a year-to-date return of 57.18%, significantly outperforming the S&P 500's return of 15.47%, which reinforces the notion that the stock is undervalued given its strong performance metrics and favorable valuation ratios....

Is CureVac NV technically bullish or bearish?

2025-09-20 20:29:39

As of 18 August 2025, the technical trend for CureVac NV has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The Bollinger Bands are bullish on the weekly and mildly bullish on the monthly, supporting a positive outlook. Daily moving averages are mildly bullish, suggesting some short-term strength. However, the KST is mildly bearish on the weekly and bullish on the monthly, adding to the mixed sentiment. CureVac has shown strong performance year-to-date with a return of 56.89%, significantly outperforming the S&P 500's 12.22%. Over the past year, it also outperformed the benchmark with a return of 62.61% compared to the S&P 500's 17.14%. However, longer-term returns over 3, 5, and 10 years are notably negative compared to the S&P 500. Overall, the current stance is mildly bullish, driven by the mixed indicators ...

Is CureVac NV overvalued or undervalued?

2025-09-20 18:48:53

As of 12 September 2025, the valuation grade for CureVac NV has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company appears undervalued, supported by a P/E ratio of 5, an EV to EBITDA of 1.90, and a PEG ratio of 0.03, all of which are considerably lower than industry norms. In comparison, PTC Therapeutics, Inc. has a P/E of 5.85 and an EV to EBITDA of 3.17, while Harmony Biosciences Holdings, Inc. shows a P/E of 11.40, highlighting CureVac's relative valuation advantage. Despite recent underperformance over shorter time frames, with a 1-week return of -0.74% compared to the S&P 500's 1.05%, CureVac has outperformed the index year-to-date with a return of 56.89% versus 12.22% for the S&P 500. This suggests that while the stock may be experiencing volatility, its long-term potential remains strong, reinforcing the view that it is currently underv...

CureVac NV Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics

2025-09-16 18:03:30

CureVac NV, a small-cap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation metrics. With a P/E ratio of 5 and strong returns on capital and equity, the company demonstrates operational efficiency and profitability, positioning itself competitively against peers in the industry.

View All News